Holen Sie sich die Stockscreener-App
7.91
30.31%
-3.44
Handel nachbörslich:
8.09
0.18
+2.28%
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Corbus Pharmaceuticals (CRBP) Reports Promising Data on CRB-701 Trial - GuruFocus
Corbus Pharmaceuticals Stock (CRBP) Opinions on Updated CRB-701 Cancer Data Release - Quiver Quantitative
Corbus Pharmaceuticals (CRBP) Analyst Sees Mispriced Weakness - GuruFocus
CRBP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Corbus Pharma (CRBP) Faces Premarket Decline Following Phase 1/2 Trial Data - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCOSlideshow (NASDAQ:CRBP) 2026-05-26 - Seeking Alpha
Corbus Pharmaceuticals stock falls on trial data release By Investing.com - Investing.com Australia
Corbus Pharmaceuticals stock falls on trial data release - Investing.com
CRB-701 data advances Corbus (NASDAQ: CRBP) OPSCC and cervical plans - Stock Titan
Corbus slips on trial data for cancer candidate (CRBP:NASDAQ) - Seeking Alpha
Corbus Pharmaceuticals Holdings Inc Pre-2026 ASCO Conference Call Transcript - GuruFocus
CRBP: CRB-701 and CRB-913 delivered promising efficacy and safety in cancer and obesity studies - TradingView
Mizuho raises Corbus Pharmaceuticals stock price target to $44 on ASCO data confidence - Investing.com Canada
CRBP: CRB-701 demonstrates strong efficacy and safety in 2L OPSCC and cervical cancer, with registrational trials planned - TradingView
Corbus Pharmaceuticals reports updated CRB-701 phase 1/2 clinical data demonstrating robust activity in 2L oropharyngeal and cervical cancers - marketscreener.com
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers - Yahoo Finance
Corbus Pharmaceuticals teases key ASCO cancer data, late-summer obesity readout - MSN
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Raises Target Price to $44 - Moomoo
CRBP Maintained by Mizuho -- Price Target Raised to $44.00 - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus (CRBP) Chief Business Officer receives RSUs and 192,300 stock options - Stock Titan
Corbus (NASDAQ: CRBP) CBO Nishant Saxena reports holding 3,500 shares - Stock Titan
Corbus Pharmaceuticals Is Maintained at Outperform by Mizuho - Moomoo
Colliers facilitates 36,471 s/f lease renewal for Corbus Pharmaceuticals - NEREJ
Mizuho raises Corbus Pharmaceuticals stock price target on ASCO preview By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call - Sahm
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout - Barchart.com
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxen - The National Law Review
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals (CRBP) grants RSUs and stock options to director - Stock Titan
Corbus Pharmaceuticals (CRBP) director granted RSUs and 12,300 stock options - Stock Titan
Corbus Pharmaceuticals (CRBP) director receives RSUs and 12,300 stock options - Stock Titan
Corbus (NASDAQ: CRBP) director Anne Altmeyer receives RSU and stock option grants - Stock Titan
Equity grants increase Corbus (CRBP) director Ben Yong’s holdings - Stock Titan
Corbus (NASDAQ: CRBP) director receives RSU and stock option grants in equity package - Stock Titan
Corbus Pharmaceuticals (CRBP) director Brent Pfeiffenberger files initial Form 3 - Stock Titan
Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer and Announces Pre-ASCO 2026 Data for CRB-701 in Oncology Trials - Minichart
Corbus Pharmaceuticals Appoints First Chief Business Officer - TipRanks
Corbus Pharmaceuticals announces the appointment of Nishant Saxena as chief business officer - marketscreener.com
Corbus appoints Brent Pfeiffenberger to board with equity awards - TradingView
Corbus Pharmaceuticals Holdings, Inc. announced that it will initiate a registration study of CRB-701 in second-line treatment for head and neck squamous cell carcinoma this summer. - Bitget
Corbus (NASDAQ: CRBP) hires Nishant Saxena as CBO, plans CRB-701 data call - Stock Titan
Corbus Pharmaceuticals Announces the Appointment of Nishant - GlobeNewswire
We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Understanding Momentum Shifts in (CRBP) - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
Corbus Pharmaceuticals Appoints Brent Pfeiffenberger to Bd of Directors - Moomoo
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Octagon/Dr. Jia report 0 shares in Corbus (CRBP) — Schedule 13G/A - Stock Titan
Corbus Pharmaceuticals appoints Brent Pfeiffenberger to board - Investing.com UK
Corbus Pharmaceuticals appoints Brent Pfeiffenberger to board By Investing.com - Investing.com Nigeria
Corbus Pharmaceuticals Appoints Brent Pfeiffenberger to Board, Advances CRB-701 and CRB-913 Clinical Programs - Minichart
Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates - TipRanks
Corbus Pharmaceuticals appoints pharma industry veteran Brent Pfeiffenberger to board of directors - marketscreener.com
Cor appoints Brent Pfeiffenberger to board as independent director - TradingView
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):